This is the authors' abstract. We don't add key points for this paper.
Acute lung injury (ALI) and its more severe form acute respiratory distress syndrome (ARDS) are acute clinical complications, which cause significant morbidity and mortality.1 Despite recent advances in our understanding of the pathophysiology and diagnosis of ALI and ARDS, the clinical strategies are restricted to mechanical ventilation and supportive treatments, such as fluid conservative management and glucocorticoids (GCs). Mechanical ventilation is a common and life-saving strategy for the patients with ARDS. Lung protective ventilation strategy with lower tidal volumes can improve hypoxia and reduce the mortality in patients with ARDS.2 GCs are potent anti-inflammatory and immune-suppressive drugs that are used therapeutically for treatment of ARDS. GCs can control inflammation and mitigate pulmonary edema. However, it has been thought that the prolongation of treatment and large dosage of GCs can cause metabolic side effects, such as super-infection, immunosuppression, and drug withdrawal. Inflammation is primarily a physiological and beneficial host response against pathogens. But non-resolving inflammatory processes may be involved in the pathogenesis and progression of many inflammatory diseases, such as ALI.3 Traditionally, anti-inflammatory drugs are the main clinical treatment for inflammation, and include non-steroid anti-inflammatory drugs, GC receptor agonists, and inhibitors targeting specific pro-inflammatory cytokines. During recent years, resolution of inflammation restores tissue homostasis, and is the new strategy for inflammatory disease. The resolution is a highly coordinated and active process that is controlled by endogenous pro-resolving mediators, which are a number of lipid mediators derived from polyunsaturated fatty acids. These pro-resolving mediators include lipoxins (LXs), E-series resolvins (RvE), D-series resolvins (RvD), and protectins/neuroprotectins. Lipoxin A4 (LXA4), lipoxin B4 (LXB4) and aspirin-triggered lipoxins (ATLs) are the first mediators biosynthesized from arachidonic acids, and stimulate the lipoxin receptor agonist/formyl-peptide receptor 2, which switchs off leukocyte trafficking to the inflammatory site, reverses vasodilation and vascular permeability, and promotes the safe disposal of inflammatory neutrophils by macrophages. Besides producing arachidonic acids derived mediators, polyunsaturated fatty acids generate omega-3 fatty acids, in particular eicosapentaenoic acid and docosahexaenoic acid, which are enzymatically transformed to generate RvE, RvD, and protectin. RvE1 and RvD1 bind to the orphan receptors ChemR23 and GPR32 respectively. Rvs and protectin share some pro-resolving and anti-inflammatory effects of LXs, which have suppressed the neutrophil infiltration and accelerated the resolution in animal models including peritonitis, ischemia/reperfusion injury, and inflammatory pain. Besides the pro-resolving mediators for inflammatory resolution, there is the peroxisome proliferator-activated receptor-γ (PPAR-γ) that belongs to a group of nuclear receptors controlling energy homeostasis, macrophage differentiation, and resolution of inflammation. 15-deoxy-Δ12,14-prostaglandin J2(15d-PGJ2) was initially identified as high affinity natural ligand for PPAR-γ that exerts its effects through PPAR-γ-dependent as well as -independent mechanisms, resulting in the suppression of various pro-inflammatory signaling pathways. It was shown that rosiglitazone, an agonist of PPAR-γ, reduces the pulmonary inflammatory response in a rat model of endotoxemia. In addition, PPAR-γ activation also enhances synthesis of LXA4 by up-regulation of 5-lipoxygenase, which is a key enzyme for production of LXA4. As we know the inflammatory responses play an important role in ALI/ARDS, and resolution of inflammation may be a novel treatment strategy for ALI/ARDS because it can limit inflammation and enhance catabasis. This idea has been supported by some reports. The lipoxin receptor agonist BML-111 can protect against hemorrhagic shock-induced ALI and VILI in rats through decreasing neutrophil accumulations, down-regulating the pro-inflammatory cytokines and suppressing NF-κB and the mitogen-activated protein kinase (MAPK) signal pathway.4-6 Meanwhile, Jin et al7 reported that posttreatment with an ATL analogue could induce the expression of HO-1 to attenuate LPS-induced ALI in mice. Pulmonary edema is due to the disruption of the paracellular alveolar barrier, which is created by tight junction and adherens junction proteins. A study found that RvD1 possesses the ability that relieve pulmonary edema and restore pulmonary capillary permeability and reduce disruption of tight junctions in LPS-induced ALI of mice, at least in part, by up-regulating HO-1 expression.8 On the basis of progress in this field, the present issue of the Chinese Medical Journal reveals studies of different aspects of inflammation to further elucidate that pro-resolution of inflammation is a potential strategy for treatment of ALI/ARDS. Neutrophils appear to play an important role in the development of ALI. Unregulated neutrophils produce a large number of proteolytic enzymes and reactive oxygen species that damage the surrounding tissues. Thus, neutrophil apoptosis is one checkpoint for the resolution of inflammation. RvD1 could promote neutrophil apoptosis in LPS-induced ALI.9 This model induced substantial injury but had low mortality over time, allowing investigation into the resolution processes from a highly injured baseline. Pretreatment with RvD1 inhibited the formation of MDA, enhanced the activity of SOD and up-regulated transcription of HO-1 gene, which suggested RvD1 displayed an anti-oxidative stress effect and alleviated LPS-induced ALI. It was also reported that protectin D1 could accelerate the resolution of LPS-induced ALI through promoting neutrophil apoptosis.10 Caspases, a group of intracellular proteases, are responsible for the deliberate disassembly of the cell into apoptotic bodies during apoptosis. Application of the pan-caspase inhibitor zVAD-fmk prevented the protectin D1-evoked reduction of neutrophil accumulation, promotion of neutrophil apoptosis, and suppression of pulmonary edema in LPS-induced ALI, indicating that protection D1-induced neutrophil apoptosis was, at least in part, caspase-dependent. In addition, PPAR-γ is found in cells of the epithelium of the respiratory tract, the submucosal layer of the bronchia, and in smooth muscles of airways, where it plays a central role in regulation of physiological functions and diseases of the respiratory system. Under stimulation by PPAR-γ agonists, PPAR-γ receptors form dimers, translocate to the nucleus, and bind to specific promoters, finally regulating the expression of inflammatory genes. Liu et al11 found that 15d-PGJ2, known as the endogenous ligand of PPAR-γ, protected against endotoxemia-induced ALI through suppressing the NF-κB signal pathway and subsequent reduction of pro-inflammatory cytokines. Wu et al12 revealed that edaravone, a free radical scavener, mitigated the endotoxemia-induced ALI in rats by inhibiting lipid peroxidation. To sum up, these reports especially from this special issue of Chinese Medical Journal indicate that pro-resolution of inflammation is a potential strategy for treatment of ALI/ARDS. However, the LXs or lipoxin receptor agonists, Rvs and protectins have not yet been used in the clinic. Fortunately, aspirin, fish oil and PPAR-γ agonists are widely used in daily medical care, and they can enhance the production of LXs and Rvs and may promote the resolution of inflammation following the ALI/ARDS. So, further clinical trials are expected to translate the idea into clinical practice.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Shang et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: